Exhibit 99.1

    Possis Reports Preliminary Fourth-Quarter Sales Above Guidance

                    Net Sales Reach $19.0 million;
              New AngioJet(R) Ultra System Drives Growth

    MINNEAPOLIS--(BUSINESS WIRE)--Aug. 15, 2007--Possis Medical, Inc.
(NASDAQ:POSS), a developer, manufacturer and marketer of pioneering
medical devices used in endovascular procedures, today reported
preliminary sales for its fiscal 2007 fourth quarter ended July 31,
2007.

    For the fourth quarter, Possis currently expects net sales of
approximately $19.0 million, an 18 percent increase from fiscal 2006
fourth-quarter sales of $16.0 million. In its outlook issued on May
23, 2007, the Company had estimated fourth-quarter net sales of $17
million to $18 million. Possis anticipates fourth quarter GAAP net
income to fall within its previously issued guidance range of $0.00 to
$0.02 per diluted share, and non-GAAP net income of $0.04 to $0.06 per
diluted share which excludes stock-based compensation expense.

    Said Robert G. Dutcher, CEO of Possis Medical, Inc., "The
Company's focus over the past two quarters has been in placing
AngioJet(R) Ultra Consoles and securing complete market access for
additional Ultra Thrombectomy Set designs. Our success in these areas
helped drive fourth-quarter results. While sales were up across the
board, we saw particular strength in Ultra Console and Thrombectomy
Set sales. As we've said previously, these are Possis' future revenue
generators and keys to growth. It's very encouraging that our efforts
are gaining traction and translating into positive financial
performance."

    The AngioJet Ultra Thrombectomy Console is the next-generation,
completely re-engineered version of Possis' proven, industry-leading
AngioJet Thrombectomy System that removes blood clots (thrombus) from
coronary arteries, coronary bypass grafts, peripheral arteries and
veins, A-V grafts and native fistulas.

    According to Dutcher, "Our coronary product line delivered
double-digit sequential growth, but importantly, increased over the
prior-year fourth quarter by 2 percent--it's our first year-over-year
increase in 12 quarters. The gain was driven by the speed and
ease-of-use the Ultra System brings to acute coronary intervention
cases."

    Possis' peripheral product sales returned to historical levels and
delivered double-digit sequential and year-over-year growth in the
fourth-quarter. The Company's AV Access product line also showed
double-digit sequential growth in the fourth-quarter. Additionally,
sales of new non-AngioJet products, such as the SafeSeal(TM)
Hemostasis Patch and the Fetch(R) Aspiration Catheter were up
sequentially and year-over-year. Beta test units of Possis'
GuardDOG(R) Occlusion Guidewire System also were shipped during the
quarter. Full U.S. market release of the GuardDOG System is expected
later this calendar year.

    The Company today also addressed its existing guidance for the
2008 fiscal year. For the 12 months ended July 31, 2008, Possis had
previously forecasted sales in the low to mid $70 million range. Said
Dutcher, "We're very pleased with our fourth-quarter performance.
While we are optimistic for fiscal 2008 and anticipate revising our
annual outlook upward, we are not making any changes at this time.
We're currently gathering additional information and experience
concerning the anticipated positive impact of the AngioJet Ultra
System launch and Dr. George Sianos' study referenced in our August
9th press release, and published recently in the Journal of the
American College of Cardiology (JACC), before updating our guidance."

    Possis will report complete fiscal 2007 fourth-quarter results on
September 19, 2007.

    About Possis Medical, Inc.

    Possis Medical, Inc., develops, manufactures and markets
pioneering medical devices for the large and growing cardiovascular
and vascular treatment markets. The Company's AngioJet System is the
world's leading mechanical thrombectomy system with FDA approval to
remove thrombus from coronary arteries, coronary bypass grafts,
peripheral arteries and veins, A-V grafts and native fistulas.

    Certain statements in this press release constitute
"forward-looking statements" within the meaning of Federal Securities
Laws. Some of these statements relate to estimated future revenue,
earnings per share, new product introductions, clinical science, and
product performance. These statements are based on our current
expectations and assumptions, and entail various risks and
uncertainties that could cause actual results to differ materially
from those expressed in such forward-looking statements, such as, the
effectiveness of our sales and marketing efforts in re-establishing
coronary product usage and launching new products. A discussion of
these and other factors that could impact the Company's future results
are set forth in the cautionary statements included in the company's
Form 10-K for the year ended July 31, 2006, filed with the Securities
and Exchange Commission.

    CONTACT: Possis Medical, Inc.
             Jules L. Fisher, 763-450-8011
             Vice President, Finance and
             Chief Financial Officer
             Jules.Fisher@possis.com